---
title: "Arsenal Medical launches EMBO-02 study to assess NeoCast in cSDH treatment"
date: "2024-11-14T17:33:21.000Z"
publishedDate: "14 novembre 2024"
summary: "Arsenal Medical today announced the initiation of the EMBO-02 clinical study of NeoCast in the treatment of chronic subdural haematomas (cSDHs). NeoCast is a first-of-its-kind, shear-responsive, non-adhesive, solvent-free, liquid embolic material designed for deep distal penetration, according to a press release from the company."
importance: ""
sourceUrl: "https://interventionalnews.com/arsenal-medical-launches-embo-02-study-to-assess-neocast-in-csdh-treatment/"
tags: ["France", "Actualité", "Interventional News — Latest"]
permalink: "/papers/2024-11-14-arsenal-medical-launches-embo-02-study-to-assess-neocast-in-csdh-treatment"
imageUrl: "https://interventionalnews.com/wp-content/uploads/sites/13/2024/11/Arsenal-Medical-logo-featured.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://interventionalnews.com/arsenal-medical-launches-embo-02-study-to-assess-neocast-in-csdh-treatment/"
---

![Arsenal Medical launches EMBO-02 study to assess NeoCast in cSDH treatment](https://interventionalnews.com/wp-content/uploads/sites/13/2024/11/Arsenal-Medical-logo-featured.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://interventionalnews.com/arsenal-medical-launches-embo-02-study-to-assess-neocast-in-csdh-treatment/*

## L’essentiel

Arsenal Medical today announced the initiation of the EMBO-02 clinical study of NeoCast in the treatment of chronic subdural haematomas (cSDHs). NeoCast is a first-of-its-kind, shear-responsive, non-adhesive, solvent-free, liquid embolic material designed for deep distal penetration, according to a press release from the company.

## Lien source

https://interventionalnews.com/arsenal-medical-launches-embo-02-study-to-assess-neocast-in-csdh-treatment/
